文献速递生殖医学

嵌合体报告对活产缺乏临床预测价值:多中心双盲验证研究

Preimplantation genetic testing for aneuploidy mosaicism reporting lacks clinical predictive value for live birth in a multisite, double-blinded study with independent validation.
PubMed 文献 · Am J Obstet Gynecol · 2025-12-16

该研究在美国生殖中心开展多中心双盲非选择研究,纳入9828例单胚胎移植(7564个IVF周期),并在欧洲5487例整倍体单胚胎移植中独立验证。移植后揭盲中间拷贝数状态,发现嵌合体报告虽与活产率轻度下降相关,但未提升含已知临床与胚胎学因素模型的预测能力,故不应指导胚胎选择。

要点

  • 嵌合体报告未改善含已知临床与胚胎学因素模型的活产预测(AUC 0.552 vs 0.555)。
  • 整倍体胚胎活产率60.0%,中间拷贝数胚胎53.2%(调整OR 0.79,95%CI 0.70-0.89)。
  • 高比例中间拷贝数仅占少数,其效应量小、发生率低,嵌合体报告不应用于常规胚胎选择。

核心结论

  • 在当前临床与实验室条件下,报告推定嵌合体不带来临床获益,不应指导常规IVF的胚胎选择。
  • 高比例中间拷贝数与活产率轻度下降相关,但因其发生率低、效应量有限,未实质性改善临床结局。

研究设计与样本

  • 在欧洲生殖中心以5487例整倍体单胚胎移植独立验证(2022年5月至2024年3月)。
  • 中间拷贝数状态在胚胎移植后揭盲,实现无偏比较。

主要发现

  • 移植后揭盲显示,84.7%(n=8328)胚胎为中间拷贝数阴性(整倍体),8.8%(n=864)为节段性中间拷贝数,5.6%(n=562)为全染色体中间拷贝数。
  • 整倍体胚胎与中间拷贝数胚胎活产率分别为60.0%与53.2%(调整OR 0.79,95%CI 0.70-0.89)。
  • 差异主要由高比例中间拷贝数小亚组驱动(P<.001;OR 0.61,95%CI 0.49-0.75)。
  • 中间拷贝数未提升含已知临床与胚胎学因素模型的预测能力(AUC 0.552 vs 0.555;所有P>.05)。
  • 各组流产、产科与新生儿结局相当。

关键数值与推荐

  • 主要结局为活产率,定义为孕24周后分娩。
  • 整倍体胚胎活产率60.0%,中间拷贝数胚胎53.2%(调整OR 0.79,95%CI 0.70-0.89)。
  • 高比例中间拷贝数亚组OR 0.61(95%CI 0.49-0.75,P<.001)。
  • 预测模型AUC 0.552 vs 0.555,所有P>.05。

临床怎么用

  • 常规IVF中不应依据推定嵌合体报告进行胚胎选择。
  • 胚胎选择应结合已确立的临床与胚胎学因素,而非嵌合体状态。
  • 对于高比例中间拷贝数胚胎,可充分告知活产率轻度下降但整体结局与整倍体相当。

局限性

  • 研究结论限于作者所在临床与实验室平台及所用检测方法。
  • 高比例中间拷贝数亚组样本量小,效应估计需谨慎解读。
  • 验证队列仅纳入欧洲中心的整倍体单胚胎移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preimplantation genetic testing for aneuploidy is used to improve in vitro fertilization outcomes by identifying embryos with lethal chromosomal abnormalities that impair development or lead to pregnancy loss. The adoption of next-generation sequencing has enabled detection of intermediate copy number deviations, often interpreted as putative mosaicism, whose clinical significance remains uncertain. OBJECTIVE: To determine whether reporting putative mosaicism based on intermediate copy number improves the prediction of reproductive outcomes and should influence embryo selection in clinical practice. STUDY DESIGN: We conducted a large, multisite, double-blinded, nonselection study across US fertility clinics (February 2020-October 2022), including 9828 single-embryo transfers from 7564 in vitro fertilization cycles. Findings were independently validated using 5487 euploid single-embryo transfers from European clinics (May 2022-March 2024). Intermediate copy number status was unblinded only after embryo transfer, allowing unbiased comparison between embryos that would have been classified as euploid or mosaic with our platform. The primary outcome for investigation in the study was live birth rate, defined as delivery after 24 weeks (gestational age). RESULTS: After unblinding the intermediate copy number status post-transfer, 84.7% (n=8328) of embryos were negative for intermediate copy number (euploid), while 8.8% (n=864) exhibited segmental intermediate copy number and 5.6% (n=562) showed whole-chromosome intermediate copy number within the current clinical and laboratory setting. A modest but statistically significant difference in live birth rate was observed between euploid embryos and those with intermediate copy number (60.0% vs 53.2%; adjusted odds ratio, 0.79; 95% confidence interval, 0.70-0.89), primarily driven by the small subset of embryos with high-level intermediate copy number (P<.001; odds ratio, 0.61; 95% confidence interval, 0.49-0.75). However, intermediate copy number did not enhance predictive models incorporating established clinical and embryological factors (area under the curve=0.552 vs 0.555; all P>.05). Miscarriage, obstetric, and neonatal outcomes were comparable across groups. CONCLUSION: Although the presence of high-level intermediate copy number in the trophectoderm biopsy was associated with a modest reduction in live birth rate, because of its low incidence and limited effect size, mosaic reporting did not contribute to a meaningful improvement in clinical outcomes. In our clinical and laboratory setting, reporting putative mosaicism provides no clinical benefit and should not guide embryo selection in routine in vitro fertilization practice.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gill P, Tao X, Zhan Y, et al. Preimplantation genetic testing for aneuploidy mosaicism reporting lacks clinical predictive value for live birth in a multisite, double-blinded study with independent validation. Am J Obstet Gynecol. 2025. PMID: 41412422. doi:10.1016/j.ajog.2025.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。